BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Syed A, Cross RK, Flasar MH. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn’s disease patients. Am J Gastroenterol. 2013;108:583-593. [PMID: 23481144 DOI: 10.1038/ajg.2012.464] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Kotze PG, Coy CS. The impact of preoperative anti-TNF in surgical and infectious complications of abdominal procedures for Crohn’s disease: controversy still persists. Am J Gastroenterol. 2014;109:139. [PMID: 24402543 DOI: 10.1038/ajg.2013.374] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Moosvi Z, Duong J, Bechtold ML, Nguyen DL. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2021;33:799-816. [PMID: 33079779 DOI: 10.1097/MEG.0000000000001944] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mizuno S, Nakazawa A, Ogawa A, Hisamatsu T, Hirose S, Tsukada N. Periappendicitis during adalimumab treatment for ileocecal Crohn’s disease in a 29-year-old male. Clin J Gastroenterol 2015;8:134-7. [DOI: 10.1007/s12328-015-0575-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ding Z, Wu X, Remer EM, Lian L, Stocchi L, Li Y, Mccullough A, Remzi FH, Shen B. Association between high visceral fat area and postoperative complications in patients with Crohn's disease following primary surgery. Colorectal Dis 2016;18:163-72. [DOI: 10.1111/codi.13128] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
5 Quezada SM, Mclean LP, Cross RK. Adverse events in IBD therapy: the 2018 update. Expert Review of Gastroenterology & Hepatology 2018;12:1183-91. [DOI: 10.1080/17474124.2018.1545574] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
6 Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn's disease. Aliment Pharmacol Ther 2014;40:1009-22. [DOI: 10.1111/apt.12947] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
7 Quaresma AB, Yamamoto T, Kotze PG. Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? Therap Adv Gastroenterol 2020;13:1756284820931738. [PMID: 32728389 DOI: 10.1177/1756284820931738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
8 Park KT, Sceats L, Dehghan M, Trickey AW, Wren A, Wong JJ, Bensen R, Limketkai BN, Keyashian K, Kin C. Risk of post-operative surgical site infections after vedolizumab vs anti-tumour necrosis factor therapy: a propensity score matching analysis in inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:340-6. [PMID: 29876995 DOI: 10.1111/apt.14842] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
9 McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol 2014;8:223-40. [PMID: 24490595 DOI: 10.1586/17474124.2014.881715] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
10 Kotze PG, Ma C, Mckenna N, Almutairdi A, Kaplan GG, Raffals LE, Loftus EV Jr, Panaccione R, Lightner AL. Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. Therap Adv Gastroenterol 2018;11:1756284818783614. [PMID: 29977340 DOI: 10.1177/1756284818783614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhu Y, Xu H, Liu W, Qi W, Yang X, Ye L, Cao Q, Zhou W. Glasgow prognostic score is a practical predictive index for postoperative intra-abdominal septic complications after bowel resection in Crohn's disease patients. Int J Colorectal Dis 2018;33:947-53. [PMID: 29687374 DOI: 10.1007/s00384-018-3035-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
12 Zangenberg MS, Horesh N, Kopylov U, El-Hussuna A. Preoperative optimization of patients with inflammatory bowel disease undergoing gastrointestinal surgery: a systematic review. Int J Colorectal Dis. 2017;32:1663-1676. [PMID: 29051981 DOI: 10.1007/s00384-017-2915-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
13 Favuzza J. Risk Factors for Anastomotic Leak, Consideration for Proximal Diversion, and Appropriate Use of Drains. Clin Colon Rectal Surg 2021;34:366-70. [PMID: 34853556 DOI: 10.1055/s-0041-1735266] [Reference Citation Analysis]
14 Lightner AL, McKenna NP, Alsughayer A, Loftus EV Jr, Raffals LE, Faubion WA, Moir C. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients. J Pediatr Surg 2019;54:2162-5. [PMID: 30773391 DOI: 10.1016/j.jpedsurg.2019.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Wils P, Leroyer A, Fumery M, Fernandez-Nistal A, Gower-Rousseau C, Pariente B. Fistulizing perianal lesions in a French population with Crohn's disease. Dig Liver Dis 2021;53:661-5. [PMID: 33551356 DOI: 10.1016/j.dld.2021.01.010] [Reference Citation Analysis]
16 Schad CA, Haac BE, Cross RK, Syed A, Lonsako S, Bafford AC. Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn’s Disease. Dig Dis Sci 2019;64:1959-66. [DOI: 10.1007/s10620-019-5476-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Saab M, Saab B, Olandoski M, Coy CSR, Kotze PG. Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review. Journal of Coloproctology 2021;35:128-36. [DOI: 10.1016/j.jcol.2015.02.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Kassel L, Hutton A, Zumach G, Rand J. Systematic review of perioperative use of immunosuppressive agents in patients undergoing bariatric surgery. Surg Obes Relat Dis 2020;16:144-57. [PMID: 31735569 DOI: 10.1016/j.soard.2019.10.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Strong S, Steele SR, Boutrous M, Bordineau L, Chun J, Stewart DB, Vogel J, Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. Clinical Practice Guideline for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2015;58:1021-36. [PMID: 26445174 DOI: 10.1097/DCR.0000000000000450] [Cited by in Crossref: 65] [Cited by in F6Publishing: 19] [Article Influence: 10.8] [Reference Citation Analysis]
20 Hanzel J, Almradi A, Istl AC, Yang ML, Fleshner KA, Parker CE, Guizzetti L, Ma C, Singh S, Jairath V. Increased Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery: Meta-Analysis. Dig Dis Sci 2021. [PMID: 33634430 DOI: 10.1007/s10620-021-06895-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ward ST, Mytton J, Henderson L, Amin V, Tanner JR, Evison F, Radley S. Anti-TNF therapy is not associated with an increased risk of post-colectomy complications, a population-based study. Colorectal Dis 2018;20:416-23. [PMID: 29059479 DOI: 10.1111/codi.13937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
22 Goodman S M, George M D. 'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'. RMD Open 2020;6:e001214. [PMID: 32719151 DOI: 10.1136/rmdopen-2020-001214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
23 Papaconstantinou I, Zeglinas C, Gazouli M, Nastos K, Yiallourou A, Papalois A, Tzathas C. The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review. J Gastrointest Surg 2014;18:1216-24. [PMID: 24599780 DOI: 10.1007/s11605-014-2487-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
24 Baddley J, Cantini F, Goletti D, Gómez-reino J, Mylonakis E, San-juan R, Fernández-ruiz M, Torre-cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clinical Microbiology and Infection 2018;24:S10-20. [DOI: 10.1016/j.cmi.2017.12.025] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 20.5] [Reference Citation Analysis]
25 Jones RG, Martino A. Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. Crit Rev Biotechnol 2016;36:506-20. [PMID: 25600465 DOI: 10.3109/07388551.2014.992388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
26 Eisner F, Küper MA, Ziegler F, Zieker D, Königsrainer A, Glatzle J. Impact of perioperative immunosuppressive medication on surgical outcome in Crohn's Disease (CD). Z Gastroenterol 2014;52:436-40. [PMID: 24824908 DOI: 10.1055/s-0033-1356347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
27 Stidham RW, Waljee AK, Day NM, Bergmans CL, Zahn KM, Higgins PD, Wang SC, Su GL. Body fat composition assessment using analytic morphomics predicts infectious complications after bowel resection in Crohn's disease. Inflamm Bowel Dis. 2015;21:1306-1313. [PMID: 25822011 DOI: 10.1097/mib.0000000000000360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.5] [Reference Citation Analysis]
28 Holubar SD, Holder-Murray J, Flasar M, Lazarev M. Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. Inflamm Bowel Dis 2015;21:2658-72. [PMID: 26422516 DOI: 10.1097/MIB.0000000000000603] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
29 Hossne RS, Sassaki LY, Baima JP, Meira Júnior JD, Campos LM. ANALYSIS OF RISK FACTORS AND POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH CROHN'S DISEASE. Arq Gastroenterol 2018;55:252-7. [PMID: 30540087 DOI: 10.1590/S0004-2803.201800000-63] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lightner AL, Mckenna NP, Alsughayer A, Harmsen WS, Taparra K, Parker ME, Raffals LE, Loftus EV. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn’s Disease: Are There Differences in the Safety Profiles? Diseases of the Colon & Rectum 2019;62:1352-62. [DOI: 10.1097/dcr.0000000000001482] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
31 Hatch QM, Ratnaparkhi R, Althans A, Keating M, Neupane R, Nishtala M, Johnson EK, Steele SR. Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease? J Gastrointest Surg 2016;20:1867-73. [PMID: 27634305 DOI: 10.1007/s11605-016-3275-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
32 Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. Dig Dis Sci 2017;62:456-64. [PMID: 27933472 DOI: 10.1007/s10620-016-4400-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
33 Mitsuya JB, Gonzalez R, Thomas R, El-baba M. The Effect of Biologics on Postoperative Complications in Children With Inflammatory Bowel Disease and Bowel Resection. Journal of Pediatric Gastroenterology & Nutrition 2019;68:334-8. [DOI: 10.1097/mpg.0000000000002159] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
34 Shwaartz C, Fields AC, Sobrero M, Cohen BD, Divino CM. Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. J Gastrointest Surg 2016;20:1636-42. [DOI: 10.1007/s11605-016-3194-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
35 Kamperidis N, Faiz O, Arebi N. The Impact of Preoperative Serum Anti-TNFα Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. Ann Surg 2017;266:e61-2. [PMID: 29136975 DOI: 10.1097/SLA.0000000000001502] [Reference Citation Analysis]
36 Xu Y, Yang L, An P, Zhou B, Liu G. Meta-Analysis: The Influence of Preoperative Infliximab Use on Postoperative Complications of Crohn’s Disease. Inflammatory Bowel Diseases 2019;25:261-9. [DOI: 10.1093/ibd/izy246] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
37 Alsaleh A, Gaidos JK, Kang L, Kuemmerle JF. Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients. Dig Dis Sci 2016;61:2602-7. [PMID: 27126205 DOI: 10.1007/s10620-016-4171-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Feuerstein JD, Jiang ZG, Belkin E, Lewandowski JJ, Martinez-vazquez M, Singla A, Cataldo T, Poylin V, Cheifetz AS. Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days: . Inflammatory Bowel Diseases 2015;21:2130-6. [DOI: 10.1097/mib.0000000000000473] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
39 Atasoy D, Aghayeva A, Bilgin İA, Erzin Y, Bayraktar İE, Baca B, Karahasanoğlu T, Hamzaoğlu İ. Predictive parameters of early postoperative complications in Crohn's disease: Single team experience. Turk J Gastroenterol 2018;29:406-10. [PMID: 30249554 DOI: 10.5152/tjg.2018.17687] [Reference Citation Analysis]
40 Choi YM, Debbaneh M, Weinberg JM, Yamauchi PS, Van Voorhees AS, Armstrong AW, Siegel M, Wu JJ. From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology 2016;75:798-805.e7. [DOI: 10.1016/j.jaad.2016.06.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
41 El-hussuna A, Myrelid P, Holubar SD, Kotze PG, Mackenzie G, Pellino G, Winter D, Davies J, Negoi I, Grewal P, Gallo G, Sahnan K, Rubio-perez I, Clerc D, Demartines N, Glasbey J, Regueiro M, Sherif AE, Neary P, Pata F, Silverberg M, Clermont S, Chadi SA, Emile S, Buchs N, Millan M, Minaya-bravo A, Elfeki H, De Simone V, Shalaby M, Gutierrez C, Ozen C, Yalçınkaya A, Rivadeneira D, Sturiale A, Yassin N, Spinelli A, Warusavitarne J, Ioannidis A, Wexner S, Mayol J; Open Source Research Collaborating Group (#OpenSourceResearch). Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. Crohn's & Colitis 360 2019;1:otz021. [DOI: 10.1093/crocol/otz021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yamamoto T, Teixeira FV, Saad-hossne R, Kotze PG, Danese S. Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. CDT 2019;20:1339-48. [DOI: 10.2174/1389450120666190404144048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
43 Nickerson TP, Merchea A. Perioperative Considerations in Crohn Disease and Ulcerative Colitis. Clin Colon Rectal Surg 2016;29:80-4. [PMID: 27247531 DOI: 10.1055/s-0036-1580633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
44 Kotze PG, Magro DO, Martinez CAR, Saab B, Saab MP, Pinheiro LV, Olandoski M, Yamamoto T, Coy CSR. Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study. Colorectal Dis. 2017;. [PMID: 29053220 DOI: 10.1111/codi.13929] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
45 Pereira R, Lago P, Faria R, Torres T. Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy: SAFETY OF ANTI-TNF THERAPIES IN IMMUNE-MEDIATED INFLAMMATORY DISEASES. Drug Dev Res 2015;76:419-27. [DOI: 10.1002/ddr.21285] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
46 Li Y, Zuo L, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Cao L, Li N, Li J. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94:e478. [PMID: 25654387 DOI: 10.1097/md.0000000000000478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
47 Fumery M, Seksik P, Auzolle C, Munoz-Bongrand N, Gornet JM, Boschetti G, Cotte E, Buisson A, Dubois A, Pariente B, Zerbib P, Chafai N, Stefanescu C, Panis Y, Marteau P, Pautrat K, Sabbagh C, Filippi J, Chevrier M, Houze P, Jouven X, Treton X, Allez M;  REMIND study group investigators. Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. Am J Gastroenterol. 2017;112:337-345. [PMID: 27958285 DOI: 10.1038/ajg.2016.541] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
48 Thomas MS, Margolin DA. Management of Colorectal Anastomotic Leak. Clin Colon Rectal Surg 2016;29:138-44. [PMID: 27247539 DOI: 10.1055/s-0036-1580630] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
49 Li Y, Stocchi L, Rui Y, Liu G, Gorgun E, Remzi FH, Shen B. Perioperative Blood Transfusion and Postoperative Outcome in Patients with Crohn's Disease Undergoing Primary Ileocolonic Resection in the "Biological Era". J Gastrointest Surg 2015;19:1842-51. [PMID: 26286365 DOI: 10.1007/s11605-015-2893-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
50 Ohge H, Mayumi T, Haji S, Kitagawa Y, Kobayashi M, Kobayashi M, Mizuguchi T, Mohri Y, Sakamoto F, Shimizu J, Suzuki K, Uchino M, Yamashita C, Yoshida M, Hirata K, Sumiyama Y, Kusachi S; Committee for Gastroenterological Surgical Site Infection Guidelines, the Japan Society for Surgical Infection. The Japan Society for Surgical Infection: guidelines for the prevention, detection, and management of gastroenterological surgical site infection, 2018. Surg Today 2021;51:1-31. [PMID: 33320283 DOI: 10.1007/s00595-020-02181-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Lin Y, Cheng S, Wang Y, Chen K, Fang C, Chen C. Systematic review with meta-analysis: risk of post-operative complications associated with pre-operative exposure to anti-tumour necrosis factor agents for Crohn’s disease. Aliment Pharmacol Ther 2019;49:966-77. [DOI: 10.1111/apt.15184] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
52 Flasar M, Syed A, Cross RK. Response to Kotze et al. Am J Gastroenterol 2014;109:139-40. [PMID: 24402544 DOI: 10.1038/ajg.2013.379] [Reference Citation Analysis]
53 Maguire LH, Alavi K, Sudan R, Wise PE, Kaiser AM, Bordeianou L. Surgical Considerations in the Treatment of Small Bowel Crohn’s Disease. J Gastrointest Surg 2017;21:398-411. [DOI: 10.1007/s11605-016-3330-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
54 Yu CS, Jung SW, Lee JL, Lim SB, Park IJ, Yoon YS, Kim CW, Yang SK, Ye BD, Park SH, Han M, Kim JC. The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease.Inflamm Bowel Dis. 2019;25:1559-1568. [PMID: 30753560 DOI: 10.1093/ibd/izz010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
55 Li Y, Zuo L, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Li N, Li J. The Impact of Bacterial DNA Translocation on Early Postoperative Outcomes in Crohn's Patients Undergoing Abdominal Surgery. Journal of Crohn's and Colitis 2015;9:259-65. [DOI: 10.1093/ecco-jcc/jju029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Zhang W, Zhu W, Ren J, Zuo L, Wu X, Li J. Skeletal muscle percentage: A protective factor for postoperative morbidity in Crohn's disease patients with severe malnutrition. J Gastrointest Surg. 2015;19:715-721. [PMID: 25666099 DOI: 10.1007/s11605-015-2763-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
57 Uchino M, Ikeuchi H, Shimizu J, Ohge H, Haji S, Mizuguchi T, Mohri Y, Yamashita C, Kitagawa Y, Suzuki K, Kobayashi M, Kobayashi M, Sakamoto F, Yoshida M, Mayumi T, Hirata K, Takesue Y. Association between preoperative tumor necrosis factor alpha inhibitor and surgical site infection after surgery for inflammatory bowel disease: a systematic review and meta-analysis. Surg Today 2021;51:32-43. [PMID: 32277281 DOI: 10.1007/s00595-020-02003-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Lightner AL, Shen B. Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". Gastroenterol Rep (Oxf) 2017;5:165-77. [PMID: 28852521 DOI: 10.1093/gastro/gow046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
59 Argeny S, Stift A, Mittlböck M, Lord AC, Maschke S, Schneeweiß M, Riss S. Advanced age impacts surgical characteristics and postoperative course in patients with Crohn's disease. Int J Surg 2016;33 Pt A:182-6. [PMID: 27535116 DOI: 10.1016/j.ijsu.2016.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
60 Jouvin I, Lefevre JH, Creavin B, Pitel S, Chafai N, Tiret E, Beaugerie L, Parc Y; Saint-Antoine IBD Network. Postoperative Morbidity Risks Following Ileocolic Resection for Crohn's Disease Treated With Anti-TNF Alpha Therapy: A Retrospective Study of 360 Patients. Inflamm Bowel Dis 2018;24:422-32. [PMID: 29361093 DOI: 10.1093/ibd/izx036] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
61 Haac BE, Nemirovsky A, Teeter W, Geyer A, Birkett RT, Cross RK, Engels M, Stein DM, Bafford AC. Injury Characteristics and Outcomes of Patients With Inflammatory Bowel Disease After Trauma: A Propensity Score Matched Analysis. Inflammatory Bowel Diseases 2020;26:1261-7. [DOI: 10.1093/ibd/izz254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol 2018;1:115-23. [PMID: 31294352 DOI: 10.1093/jcag/gwy013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
63 Law CC, Bell C, Koh D, Bao Y, Jairath V, Narula N. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Cochrane Database Syst Rev 2020;10:CD013256. [PMID: 33098570 DOI: 10.1002/14651858.CD013256.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Buhr H, Kroesen A. Therapierefraktäre chronisch entzündliche Darmerkrankungen: Eine chirurgische Herausforderung. Chirurg 2013;84:945-50. [DOI: 10.1007/s00104-013-2516-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
65 Patil SA, Cross RK. Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives. Expert Rev Gastroenterol Hepatol 2017;11:843-8. [PMID: 28633544 DOI: 10.1080/17474124.2017.1342536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Yamamoto T, Spinelli A, Suzuki Y, Saad-Hossne R, Teixeira FV, de Albuquerque IC, da Silva RN, de Barcelos IF, Takeuchi K, Yamada A, Shimoyama T, da Silva Kotze LM, Sacchi M, Danese S, Kotze PG. Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterol J 2016;4:784-93. [PMID: 28408996 DOI: 10.1177/2050640615600116] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
67 Law CCY, Koh D, Bao Y, Jairath V, Narula N. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.Inflamm Bowel Dis. 2020;26:1796-1807. [PMID: 32047894 DOI: 10.1093/ibd/izaa020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Vilchez V, Lightner AL. Perioperative management of biologic agents in Crohn's disease. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100865] [Reference Citation Analysis]
69 Zimmerman LA, Saites CG, Bairdain S, Lien C, Zurakowski D, Shamberger RC, Linden BC, Bousvaros A. Postoperative Complications in Children With Crohn Disease Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2016;63:352-6. [DOI: 10.1097/mpg.0000000000001151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
70 Yang ZP, Hong L, Wu Q, Wu KC, Fan DM. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg. 2014;12:224-230. [PMID: 24394691 DOI: 10.1016/j.ijsu.2013.12.015] [Cited by in Crossref: 95] [Cited by in F6Publishing: 80] [Article Influence: 11.9] [Reference Citation Analysis]
71 Lightner AL. Surgery for Inflammatory Bowel Disease in the Era of Biologics. J Gastrointest Surg 2020;24:1430-5. [PMID: 32253646 DOI: 10.1007/s11605-020-04563-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:1057-1064. [PMID: 23581515 DOI: 10.1111/apt.12313] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 12.0] [Reference Citation Analysis]
73 Qiu Y, Zheng Z, Liu G, Zhao X, He A. Effects of preoperative anti-tumour necrosis factor alpha infusion timing on postoperative surgical site infection in inflammatory bowel disease: A systematic review and meta-analysis. United European Gastroenterol J 2019;7:1198-214. [PMID: 31700633 DOI: 10.1177/2050640619878998] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Byrne LW, McKay D. Does perioperative biological therapy increase 30-day post-operative complication rates in inflammatory bowel disease patients undergoing intra-abdominal surgery? A systematic review. Surgeon 2021;19:e153-67. [PMID: 34581275 DOI: 10.1016/j.surge.2020.09.001] [Reference Citation Analysis]
75 Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn’s disease in the biological era: Systematic review and meta-analysis. World J Gastrointest Surg 2016; 8(3): 274-283 [PMID: 27022455 DOI: 10.4240/wjgs.v8.i3.274] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
76 Chang MI, Cohen BL, Greenstein AJ. A review of the impact of biologics on surgical complications in Crohn's disease. Inflamm Bowel Dis 2015;21:1472-7. [PMID: 25811432 DOI: 10.1097/MIB.0000000000000362] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
77 Tang S, Dong X, Liu W, Qi W, Ye L, Yang X, Cao Q, Ge X, Zhou W. Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study.Int J Colorectal Dis. 2020;35:727-737. [PMID: 32060607 DOI: 10.1007/s00384-019-03481-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]